{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:54:06Z","timestamp":1792468446611,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1124\/dmd.105.006445","type":"journal-article","created":{"date-parts":[[2005,11,5]],"date-time":"2005-11-05T01:43:23Z","timestamp":1131155003000},"page":"471-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["CHARACTERIZATION OF HUMAN CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF THE PIPERIDINE-TYPE PHENOTHIAZINE NEUROLEPTIC THIORIDAZINE"],"prefix":"10.1016","volume":"34","author":[{"given":"Jacek","family":"W\u00f3jcikowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Maurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W\u0142adys\u0142awa A.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.105.006445_bib1","first-page":"587","article-title":"On the serum concentrations and antipsychotic effects of thioridazine, thioridazine side-chain sulfoxide and thioridazine side-chain sulfone in chronic psychotic patients.","volume":"21","author":"Axelsson","year":"1977","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1124\/dmd.105.006445_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00228-003-0576-4","article-title":"Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.","volume":"59","author":"Berecz","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.105.006445_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-3565(25)32494-8","article-title":"Interactions of neuroleptic metabolites with dopaminergic, alpha adrenergic and muscarinic cholinergic receptors.","volume":"217","author":"Bylund","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.105.006445_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF00439552","article-title":"A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites.","volume":"97","author":"Cohen","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1124\/dmd.105.006445_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0940-2993(99)80012-8","article-title":"The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies.","volume":"51","author":"Daniel","year":"1999","journal-title":"Exp Toxicol Pathol"},{"key":"10.1124\/dmd.105.006445_bib6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bjp.0703540","article-title":"Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants.","volume":"131","author":"Daniel","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.105.006445_bib7","first-page":"439","article-title":"Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment.","volume":"49","author":"Daniel","year":"1997","journal-title":"Pol J Pharmacol"},{"key":"10.1124\/dmd.105.006445_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jps.2600670208","article-title":"Plasma concentrations of thioridazine metabolites and ECG abnormalities.","volume":"67","author":"Gottschalk","year":"1978","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.105.006445_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/0041-008X(86)90398-4","article-title":"Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart.","volume":"86","author":"Hale","year":"1986","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.105.006445_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005053-197708000-00008","article-title":"Cardiac toxicity with thioridazine-tricyclic antidepressant combination.","volume":"165","author":"Heiman","year":"1977","journal-title":"J Nerv Ment Dis"},{"key":"10.1124\/dmd.105.006445_bib11","first-page":"1454","article-title":"Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4.","volume":"29","author":"Hustert","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.006445_bib12","series-title":"Dyskinesia\u2014Research and Treatment","first-page":"9","article-title":"Receptor binding profiles of neuroleptics","author":"Hyttel","year":"1985"},{"key":"10.1124\/dmd.105.006445_bib13","series-title":"Structures and Function","first-page":"76","article-title":"Substrate selectivity and metabolism, in Cytochromes P450.","author":"Lewis","year":"2001"},{"key":"10.1124\/dmd.105.006445_bib14","article-title":"Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat.","volume":"23","author":"Lin","year":"1993","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.105.006445_bib15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/026988110201600411","article-title":"QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients.","volume":"16","author":"Llerena","year":"2002","journal-title":"J Psychopharmacol"},{"key":"10.1124\/dmd.105.006445_bib16","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00007691-200112000-00004","article-title":"Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.","volume":"23","author":"Llerena","year":"2001","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.105.006445_bib17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00007691-200008000-00006","article-title":"Use of the mesoridazine\/thioridazine ratio as a marker for CYP2D6 enzyme activity.","volume":"22","author":"Llerena","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.105.006445_bib18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/BF00316110","article-title":"Clinical implications of slow sulphoxidation of thioridazine in poor metabolizer of the debrisoquine type.","volume":"39","author":"Meyer","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.105.006445_bib19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/00498258509045365","article-title":"Phenolic metabolites of thioridazine in man.","volume":"15","author":"Papadopoulos","year":"1985","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.105.006445_bib20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0014-2999(84)90478-3","article-title":"Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro.","volume":"103","author":"Richelson","year":"1984","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.105.006445_bib21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.105.006445_bib22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/BF00179183","article-title":"HPLC with electrochemical detection to measure chlorpromazine, thioridazine and metabolites in human brain.","volume":"90","author":"Svendsen","year":"1986","journal-title":"Psychopharmacology"},{"key":"10.1124\/dmd.105.006445_bib23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/clpt.1991.22","article-title":"Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.","volume":"49","author":"von Bahr","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.105.006445_bib24","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/sj.bjp.0705195","article-title":"Contribution of human cytochrome P-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.","volume":"138","author":"W\u00f3jcikowski","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.105.006445_bib25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0924-977X(03)00105-6","article-title":"The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes.","volume":"14","author":"W\u00f3jcikowski","year":"2004","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624034287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624034287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.105.006445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:01:00Z","timestamp":1739901660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624034287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0090955624034287"],"URL":"https:\/\/doi.org\/10.1124\/dmd.105.006445","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CHARACTERIZATION OF HUMAN CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF THE PIPERIDINE-TYPE PHENOTHIAZINE NEUROLEPTIC THIORIDAZINE","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.105.006445","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2006 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}